JP2002536404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002536404A5 JP2002536404A5 JP2000598148A JP2000598148A JP2002536404A5 JP 2002536404 A5 JP2002536404 A5 JP 2002536404A5 JP 2000598148 A JP2000598148 A JP 2000598148A JP 2000598148 A JP2000598148 A JP 2000598148A JP 2002536404 A5 JP2002536404 A5 JP 2002536404A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- disease
- agent
- agent according
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 73
- 239000000556 agonist Substances 0.000 claims description 32
- 208000011231 Crohn disease Diseases 0.000 claims description 23
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 20
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 20
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims description 20
- 230000003308 immunostimulating effect Effects 0.000 claims description 16
- 206010016717 Fistula Diseases 0.000 claims description 10
- 230000003890 fistula Effects 0.000 claims description 10
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims description 9
- 210000000440 neutrophil Anatomy 0.000 claims description 8
- 239000000816 peptidomimetic Substances 0.000 claims description 8
- 230000008378 epithelial damage Effects 0.000 claims description 6
- 210000003714 granulocyte Anatomy 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 5
- 206010048946 Anal abscess Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000017283 Bile Duct disease Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010015084 Episcleritis Diseases 0.000 claims description 2
- 206010015226 Erythema nodosum Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 208000006311 Pyoderma Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 208000028299 esophageal disease Diseases 0.000 claims description 2
- 208000005516 glycogen storage disease Ib Diseases 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 5
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000002389 Pouchitis Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000000712 G cell Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 108010032539 nartograstim Proteins 0.000 description 2
- 229950010676 nartograstim Drugs 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11984299P | 1999-02-12 | 1999-02-12 | |
| US60/119,842 | 1999-02-12 | ||
| PCT/US2000/003407 WO2000047195A1 (en) | 1999-02-12 | 2000-02-11 | Stimulating neutrophil function to treat inflammatory bowel disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005124264A Division JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002536404A JP2002536404A (ja) | 2002-10-29 |
| JP2002536404A5 true JP2002536404A5 (enExample) | 2006-02-09 |
Family
ID=22386711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000598148A Withdrawn JP2002536404A (ja) | 1999-02-12 | 2000-02-11 | 炎症性腸疾患を治療するための好中球機能の刺激 |
| JP2005124264A Pending JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005124264A Pending JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1150666B1 (enExample) |
| JP (2) | JP2002536404A (enExample) |
| AT (1) | ATE446767T1 (enExample) |
| AU (1) | AU764681C (enExample) |
| CA (1) | CA2367575A1 (enExample) |
| DE (1) | DE60043216D1 (enExample) |
| WO (1) | WO2000047195A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500418B1 (en) | 1999-02-12 | 2002-12-31 | The Washington University | Stimulating neutrophil function to treat inflammatory bowel disease |
| WO2004100972A1 (ja) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | 組織破壊を伴う疾患の予防及び／または治療剤 |
| WO2005084702A1 (ja) * | 2004-03-02 | 2005-09-15 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
| WO2007134907A2 (en) * | 2006-05-18 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| NZ228031A (en) * | 1984-07-06 | 1991-12-23 | Sandoz Ltd | Primate gm-csf and method of extraction |
| ZA856108B (en) * | 1984-10-29 | 1986-10-29 | Immunex Corp | Cloning of human granulocyte-macrophage colony simulating factor gene |
| WO1988010310A1 (en) * | 1987-06-25 | 1988-12-29 | Immunex Corporation | Bovine granulocyte-macrophage colony stimulating factor |
| US4961926A (en) * | 1987-11-19 | 1990-10-09 | Sloan-Kettering Institute For Cancer Research | Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| WO1995009622A1 (en) * | 1993-10-06 | 1995-04-13 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| US5733915A (en) * | 1995-03-30 | 1998-03-31 | Glaxo Wellcome Inc. | Use of azathioprine to treat crohn's disease |
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| WO1998043667A1 (en) * | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
| DE19835080A1 (de) * | 1998-07-27 | 2000-02-03 | Doecke Wolf Dietrich | Mittel zur Behandlung des Krankheitsbildes Morbus Crohn |
-
2000
- 2000-02-11 AT AT00913421T patent/ATE446767T1/de not_active IP Right Cessation
- 2000-02-11 CA CA002367575A patent/CA2367575A1/en not_active Abandoned
- 2000-02-11 AU AU34871/00A patent/AU764681C/en not_active Ceased
- 2000-02-11 JP JP2000598148A patent/JP2002536404A/ja not_active Withdrawn
- 2000-02-11 DE DE60043216T patent/DE60043216D1/de not_active Expired - Lifetime
- 2000-02-11 EP EP00913421A patent/EP1150666B1/en not_active Expired - Lifetime
- 2000-02-11 WO PCT/US2000/003407 patent/WO2000047195A1/en not_active Ceased
-
2005
- 2005-04-21 JP JP2005124264A patent/JP2005225890A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith 2nd et al. | The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. | |
| JP2012515222A5 (enExample) | ||
| US8920790B2 (en) | Uses of IL-12 in hematopoiesis | |
| JP2018165271A (ja) | 多発性硬化症を治療するためのクラドリビン投薬計画 | |
| Joseph Giles | Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants | |
| US5718893A (en) | Use of G-CSF to reduce acute rejection | |
| US5178855A (en) | Treatment of luekocyte dysfunction with GM-CSF | |
| JP2002536404A5 (enExample) | ||
| CN101528251B (zh) | 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂 | |
| US5536495A (en) | Use of G-CSF to reduce acute rejection | |
| Nielsen | Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF; filgrastim) treatment of clozapine‐induced agranulocytosis | |
| Veldhuis et al. | Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. | |
| Tate et al. | Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects | |
| EP1641431B1 (en) | Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy | |
| AU2001279235A1 (en) | Stimulating neutrophil function to treat inflammatory bowel disease | |
| EP1309339A2 (en) | Stimulating neutrophil function to treat inflammatory bowel disease | |
| Legrand et al. | Treatment of hairy cell leukaemia (HCL) with 2‐chlorodeoxyadenosine (2‐CdA): identification of parameters predictive of adverse effects | |
| JPH09510737A (ja) | 化学療法剤を増強するためのｉｌ−４の使用 | |
| Bauhofer et al. | Effects of G-CSF and antibiotic prophylaxis in a 2× 2 factorial design on outcome in septic rats | |
| Dimitrijevic et al. | Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors | |
| Crawford et al. | Hematopoietic growth factors | |
| Christopoulos et al. | The place of myeloid growth factors in the treatment of hairy‐cell leukaemia | |
| JP2003512432A (ja) | 腫瘍患者または慢性もしくは消耗性疾患を有する患者の一般状態を改善するためのパルボウイルスの使用 | |
| HK1132461B (en) | Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |